Anaphylaxis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
#Criterion 1 (90% of pts) | #Criterion 1 (90% of pts) | ||
##Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following: | ##Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following: | ||
###Respiratory | ###[[Respiratory Compromise]] | ||
###Reduced BP or associated symptoms ( | ###Reduced BP or associated symptoms ([[Syncope]], [[Dizziness]]) | ||
#Criterion 2 (10-20% of pts) | #Criterion 2 (10-20% of pts) | ||
##TWO OR MORE of the following that that occur rapidly after exposure to a LIKELY allergen for that pt | ##TWO OR MORE of the following that that occur rapidly after exposure to a LIKELY allergen for that pt | ||
###Involvement of the skin-mucosal tissue (hives, swollen lips-tongue-uvula) | ###Involvement of the skin-mucosal tissue (hives, swollen lips-tongue-uvula) | ||
###Respiratory | ###[[Respiratory Compromise]] | ||
###Reduced BP or associated symptoms | ###[[Reduced BP]] or associated symptoms | ||
###Persistent GI symptoms ( | ###Persistent GI symptoms ([[Vomiting]], [[Diarrhea]], crampy [[Abd Pain]]) | ||
#Criterion 3 | #Criterion 3 | ||
##Reduced BP after exposure to a KNOWN allergy for that pt (minutes to hours): | ##[[Reduced BP]] after exposure to a KNOWN allergy for that pt (minutes to hours): | ||
###Adults | ###Adults | ||
####Systolic < 90 or > 30% from baseline | ####Systolic < 90 or > 30% from baseline | ||
| Line 60: | Line 60: | ||
###IV infusion - 0.05-1 mcg/kg/min | ###IV infusion - 0.05-1 mcg/kg/min | ||
#Oxygen | #Oxygen | ||
##Consider | ##Consider [[Intubation]] if e/o airway edema | ||
#NS bolus | #NS bolus | ||
##If unresponsive to Epi assume distributive | ##If unresponsive to [[Epi]] assume distributive [[Shock]] (give NS 1-2L) | ||
#Glucagon 1-2mg IV over 5 min followed by infusion of 5-15µg/min | #Glucagon 1-2mg IV over 5 min followed by infusion of 5-15µg/min | ||
##If on B-blocker AND unresponsive to | ##If on B-blocker AND unresponsive to [[Epi]] | ||
#Also consider: | #Also consider: | ||
##Albuterol: For bronchospasm resistant to IM epinephrine | ##Albuterol: For bronchospasm resistant to IM epinephrine | ||
Revision as of 21:15, 31 March 2012
Background
Definition
Highly likely when ANY ONE of the following criteria is fulfilled:
- Criterion 1 (90% of pts)
- Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following:
- Respiratory Compromise
- Reduced BP or associated symptoms (Syncope, Dizziness)
- Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following:
- Criterion 2 (10-20% of pts)
- TWO OR MORE of the following that that occur rapidly after exposure to a LIKELY allergen for that pt
- Involvement of the skin-mucosal tissue (hives, swollen lips-tongue-uvula)
- Respiratory Compromise
- Reduced BP or associated symptoms
- Persistent GI symptoms (Vomiting, Diarrhea, crampy Abd Pain)
- TWO OR MORE of the following that that occur rapidly after exposure to a LIKELY allergen for that pt
- Criterion 3
- Reduced BP after exposure to a KNOWN allergy for that pt (minutes to hours):
- Adults
- Systolic < 90 or > 30% from baseline
- Peds
- Less than 70 mmHg from 1 month up to 1 year
- Less than (70 mmHg + [2 x age]) from 1 to 10 years
- Less than 90 mmHg from 11 to 17 years
- Adults
- Reduced BP after exposure to a KNOWN allergy for that pt (minutes to hours):
Course
- Uniphasic (80-90%)
- Symptoms peak within 30min-1hr after onset, resolves within 30min-1hr of receiving Tx
- Biphasic (10-20%)
- Uniphasic response, followed by asymptomatic period of hour or more, then return of symptoms
- The second phase does not necessarily resemble the first!
- Possible risk factors
- Severe initial symptoms
- Late administration of epi
- Delayed resolution of initial symptoms
- Little evidence that glucocorticoids blunt a biphasic presentation
- Protracted (case reports)
- Lasts hours to days without resolving completely
DDX
- Generalized urticaria
- Angioedema
- Asthma exacerbation
- Anxiety attack
- MI
- Scombroidosis
- Other forms of shock
Diagnosis
Presentation
- Cutaneous symptoms - 90%
- Respiratory symptoms - 70%
- GI symptoms - 40%
- Cardiovascular symptoms - 35%
Treatment
- Epinephrine 1:1000 IM 0.3-0.5mg (0.3-0.5mL) Q5-15min
- Give as soon as possible
- Always IM initially
- Start epinephrine infusion 1:10,000 2-10µg/min if inadequate response to IM
- Peds
- IM - 0.01mg/kg/dose (max 0.5mg)
- IV infusion - 0.05-1 mcg/kg/min
- Oxygen
- Consider Intubation if e/o airway edema
- NS bolus
- Glucagon 1-2mg IV over 5 min followed by infusion of 5-15µg/min
- If on B-blocker AND unresponsive to Epi
- Also consider:
- Albuterol: For bronchospasm resistant to IM epinephrine
- Antihistamines
- Only for sympton control (hives, itching) AFTER hemodynamically stable
- Diphenhydramine 25 to 50 mg IV
- Ranitidine 50 mg IV (minimal evidence to support this)
- Only for sympton control (hives, itching) AFTER hemodynamically stable
- Glucocorticoid: May blunt biphasic reaction
- Methylprednisolone 125 mg IV (2mg/kg in peds)
- Three day PO course (biphasic reaction always occurs within 72hrs)
Disposition
- Admit: Severe and moderate (especially if symptoms did not respond promptly to epi)
- Home: Symptom-free for at least 4hr
- Send home with an epi autoinjector!
See Also
Sources
- Brown SGA, Mullins RJ and Gold MS, Anaphylaxis: diagnosis and management, MJA 2006; 185: 283–289
- Ewan PW, ABC of allergies – Anaphylaxis, BMJ 1998; 316: 1442-1445
- Simons FER, Gu X, Simons KJ, Epinephrine absorption in adults: Intramuscular versus subcutaneous injection, J Allergy Clin Immunol 2001;108:871-3
- Lieberman P et al, The diagnosis and management of anaphyalxis: An updated practice parameter, J Allergy Clin Immunol 2005;115;3:S483-S523
- Sheikh A, Shehata YA, Brown SGA, Simons FER. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock.Cochrane Database of Systematic Reviews2008, Issue 4. Art. No.: CD006312. DOI:10.1002/14651858.CD006312.pub2
- Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
- Tintinalli's Emergency Medicine
